Tyme Technologies (NASDAQ:TYME) reported updated results from its Phase 2 trial of SM-88 in patients with pancreatic cancer.
SM-88 is a modified tyrosine derivative designed to disrupt cancer cell metabolism and cause cancer cell death.
The Phase 2 trial was performed in 49 heavily pre-treated patients, more than 80% of which had received at least two prior lines of therapy.
As of April 25, 2019, the median overall survival of evaluable patients was 6.4 months. As defined by the response evaluation criteria in solid tumors, clinical benefit rate of stable disease, or better, was achieved in 44% of patients. These patients demonstrated a statistically significant improvement in survival, with a 92% reduction in risk of death.
“The SM-88 trial has demonstrated encouraging new data on efficacy indicators, including a meaningful clinical benefit rate, and a reduction in circulating tumor cells, that both correlate with extended survival,” Dr. Allyson Ocean, a pancreatic cancer specialist at New York-Presbyterian Hospital/Weill Cornell Medical Center, said in a statement.
Tyme plans to initiate a pivotal trial for SM-88 in patients with pancreatic cancer in the third quarter of 2019.
